Abbott’s acquisition of Alere: reshaping the market for rapid medical tests

Abbott Laboratories (NYSE:ABT) announced on February 1st, 2016 the acquisition of Alere (NYSE:ALR). The deal comes just few days after Abbott reported a drop of 15% in its profits for the final quarter of 2015, mainly linked to the stronger dollar effects on its results in the Emerging Markets where it sells its products. The … Continue reading Abbott’s acquisition of Alere: reshaping the market for rapid medical tests

Pfizer – Allergan

A new Pharma Mega-Deal making Botox and Viagra join forces. On November 23, 2015, Pfizer announced its $160bn tie-up with Allergan to form the world’s biggest pharmaceutical company by sales. Industry Overview Even though recent M&A activity has started to slow down in the healthcare sector, the announced merger shows that the M&A frenzy is … Continue reading Pfizer – Allergan

Pfizer’s acquisition of Hospira, the M&A wave in the healthcare sector still far from settling down

In February 2015, Pfizer announced that it wants to acquire its smaller rival Hospira to make Pfizer the leading producer in the biosimilars sector, a high-growth niche sector focusing on lower cost biotech pharmaceuticals. Industry Overview The chart below shows that pharmaceutical stocks significantly outperformed general markets up until Q3 2015. The healthcare M&A market … Continue reading Pfizer’s acquisition of Hospira, the M&A wave in the healthcare sector still far from settling down

A NEW OUTBURST OF THE HEALTHCARE M&A FIRE – TEVA TO ACQUIRE ALLERGAN

Teva Pharmaceutical Industries will pay $40.5bn in cash and stock for Allergan’s generic drug business, sustaining Teva’s position as the world’s number one producer of generics. Industry Overview Teva Pharmaceutical Industries Ltd. is an international pharmaceutical company with its headquarters in Israel. Its main business is producing generic drugs, but it also has business in … Continue reading A NEW OUTBURST OF THE HEALTHCARE M&A FIRE – TEVA TO ACQUIRE ALLERGAN

A “LOWBALL OPENING” – SHIRE’S TAKEOVER OFFER FOR BAXALTA

Shire made a $30bn (£19bn) hostile takeover bid for Baxalta. Industry overview Shire is a London-listed drug company, with tax domicile in Ireland and Jersey. Shire develops and provides healthcare in the areas of behavioral health, gastrointestinal conditions, rare diseases, and regenerative medicine. Its main business lies in the area of Attention Deficit Hyperactive Disorder (ADHD) - … Continue reading A “LOWBALL OPENING” – SHIRE’S TAKEOVER OFFER FOR BAXALTA

GENERICALLY SPEAKING, HEALTHCARE M&A IS ON FIRE

Industry Overview During the past weeks we observed a lot of activity in the healthcare sector centering around three companies: Mylan, Perrigo and Teva. Mylan is a Dutch pharmaceutical company headquartered in Amsterdam. It is among the largest generics and specialist pharmaceutical companies in the world, manufacturing and marketing approximately 1,400 pharmaceutical products. Mylan’s business … Continue reading GENERICALLY SPEAKING, HEALTHCARE M&A IS ON FIRE

THE END OF A TRILOGY – VALEANT ON SALIX CASE.

The increased M&A activity within the Healthcare sector has not slowed down in 2015, after we saw a record volume of transactions in the previous year. After securing financing, Canada-based Valeant has won a tender offer for Salix Pharmaceuticals, in a $14.5bn transaction. The market trend of increased deal activity for tax-inverted players still continues. … Continue reading THE END OF A TRILOGY – VALEANT ON SALIX CASE.

GLAXOSMITHKLINE & NOVARTIS SWAP ASSTES WORTH £11BN

The asset-swap between GlaxoSmithKline (NYSE: GSK) and Novartis (NYSE: NVS) will lead to stronger focus by both companies on their current core activities. The transaction sets a new framework for future complex deals, where participants enhance their operations by divesting from non-profitable divisions, while acquiring assets that enhance the current portfolios. GSK’s position in vaccines … Continue reading GLAXOSMITHKLINE & NOVARTIS SWAP ASSTES WORTH £11BN

ACTAVIS ACQUIRES BOTOX-MAKER ALLERGAN FOR $66BN

The acquisition of Allergan Inc. (NYSE:AGN) by Actavis Plc. (NYSE:ACT) will lead to the creation of one of the biggest pharmaceutical companies in the world. The $66bn deal is expected to be closed by the second quarter of 2015. The acquisition by Actavis brings an end to the months-long pursuit of Allergan by the Canadian … Continue reading ACTAVIS ACQUIRES BOTOX-MAKER ALLERGAN FOR $66BN